PolyPid Ltd. Ordinary Shares (PYPD) is a publicly traded Healthcare sector company. As of May 21, 2026, PYPD trades at $4.85 with a market cap of $90.69M and a P/E ratio of 0.00. PYPD moved +2.10% today. Year to date, PYPD is +8.50%; over the trailing twelve months it is +67.24%. Its 52-week range spans $2.30 to $5.12. Analyst consensus is strong buy with an average price target of $11.00. Rallies surfaces PYPD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PolyPid Begins Phase III PXL01 Trial After Q1 Net Loss of $9.4M: PolyPid reported a Q1 net loss of $9.4M on zero revenue and ended March with $38.1M cash, following a $20M April equity raise. Management commenced a Phase III trial for its PXL01 analgesic patch and struck a distribution pact in Europe.
| Metric | Value |
|---|---|
| Price | $4.85 |
| Market Cap | $90.69M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.12 |
| 52-Week Low | $2.30 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover PYPD: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.00.